Research guide · Metabolic Support
Cagrilintide — research protocol
Amylin analog studied for appetite regulation and metabolic control.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Long-acting amylin analog
- Metabolic compound
- Lyophilized stability
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
Cagrilintide is a once-weekly research peptide developed by Novo Nordisk, a long-acting analogue of amylin designed to make people feel full sooner, stay full longer, and slow gastric emptying. It is currently in Phase 3 development for monotherapy and in combination with semaglutide.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Initiation | 0.25 mg | once weekly | Weeks 1-4 | Subcutaneous injection |
| Step 2 | 0.5 mg | once weekly | Weeks 5-8 | Subcutaneous injection |
| Step 3 | 1.0 mg | once weekly | Weeks 9-12 | Subcutaneous injection |
| Maintenance | 2.4 mg | once weekly | Weeks 17+ | Subcutaneous injection |
Cycle: Common research cycles range from 16 to 68 weeks, with 16 weeks reaching the maintenance dose and longer cycles matching published trial endpoints.
Benefits and research observations: Monitor GI tolerance, body weight, and blood pressure, especially during weeks 1-12 of dose escalation. Glycemic markers and gallbladder symptoms should also be monitored if applicable.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Lau DCW, et al. Lancet, 2021.
- 2.Enebo LB, et al. Lancet, 2021.